Correction to: Prolotherapy agent P2G is associated with upregulation of fibroblast growth factor-2 genetic expression in vitro (Journal of Experimental Orthopaedics, (2020), 7, 1, (97), 10.1186/s40634-020-00312-z)

Elisha Johnston, Chandrakanth Emani, Andrew Kochan, Kidane Ghebrehawariat, John Tyburski, Michael Johnston, David Rabago

Research output: Contribution to journalComment/debatepeer-review

Abstract

Following publication of the original article [1], the below Abstract was missing. Abstract Purpose: Osteoarthritis (OA) is a prevalent, progressively degenerative disease. Researchers have rigorously documented clinical improvement in participants receiving prolotherapy for OA. The mechanism of action is unknown; therefore, basic science studies are required. One hypothesized mechanism is that prolotherapy stimulates tissue proliferation, including that of cartilage. Accordingly, this in vitro study examines whether the prolotherapy agent phenol-glycerin-glucose (P2G) is associated with upregulation of proliferation-enhancing cytokines, primarily fibroblast growth factor-2 (FGF-2). Methods: Murine MC3T3-E1 cells were cultured in a nonconfluent state to retain an undifferentiated osteochondroprogenic status. A limitation of MC3T3-E1 cells is that they do not fully reproduce primary human chondrocyte phenotypes; however, they are useful for modeling cartilage regeneration in vitro due to their greater phenotypic stability than primary cells. Two experiments were conducted: one in duplicate and one in triplicate. Treatment consisted of phenol-glycerin-glucose (P2G, final concentration of 1.5%). The results were assessed by quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) to detect mRNA expression of the FGF-2, IGF-1, CCND-1 (Cyclin-D), TGF-ß1, AKT, STAT1, and BMP2 genes. Results: P2G - treated preosteoblasts expressed higher levels of FGF-2 than water controls (hour 24, p<0.001; hour 30, p<0.05; hour 38, p<0.01). Additionally, CCND- 1 upregulation was observed (p<0.05), possibly as a cellular response to FGF-2 upregulation. Conclusions: The prolotherapy agent P2G appears to be associated with upregulation of the cartilage cell proliferation enhancer cytokine FGF-2, suggesting an independent effect of P2G consistent with clinical evidence. Further study investigating the effect of prolotherapy agents on cellular proliferation and cartilage regeneration is warranted. The original article [1] has been corrected.

Original languageEnglish (US)
Article number100
JournalJournal of Experimental Orthopaedics
Volume7
Issue number1
DOIs
StatePublished - Dec 2020

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'Correction to: Prolotherapy agent P2G is associated with upregulation of fibroblast growth factor-2 genetic expression in vitro (Journal of Experimental Orthopaedics, (2020), 7, 1, (97), 10.1186/s40634-020-00312-z)'. Together they form a unique fingerprint.

Cite this